Synthis Tx is developing a first in class, cell targeted TGF-b inhibitor that drives immune mediated tumor clearance, with reduced systemic toxicity. TGF-b is a validated tumor promoting pathway but systemic TGFb inhibitors cause host toxicity. Our lead drug, SYN101, inhibits tumor growth and improves immune effector function in vivo as a monotherapy. We are raising a $3M seed round for safety, PK and dose funding, key derisking milestones.